Murphy Pohlad Asset Management LLC maintained its stake in SurModics, Inc. (NASDAQ:SRDX) during the first quarter, Holdings Channel reports. The firm owned 64,150 shares of the company’s stock at the end of the first quarter. Murphy Pohlad Asset Management LLC owned 0.48% of SurModics worth $1,542,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in SRDX. Prudential Financial Inc. raised its position in shares of SurModics by 7.3% in the third quarter. Prudential Financial Inc. now owns 50,032 shares of the company’s stock valued at $1,506,000 after buying an additional 3,410 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of SurModics by 6.7% in the third quarter. JPMorgan Chase & Co. now owns 400,974 shares of the company’s stock valued at $12,065,000 after buying an additional 25,249 shares during the last quarter. Menta Capital LLC raised its position in shares of SurModics by 2.9% in the fourth quarter. Menta Capital LLC now owns 89,148 shares of the company’s stock valued at $2,264,000 after buying an additional 2,500 shares during the last quarter. Capstone Asset Management Co. raised its position in shares of SurModics by 1.6% in the third quarter. Capstone Asset Management Co. now owns 8,780 shares of the company’s stock valued at $264,000 after buying an additional 140 shares during the last quarter. Finally, Systematic Financial Management LP raised its position in shares of SurModics by 21.2% in the fourth quarter. Systematic Financial Management LP now owns 50,765 shares of the company’s stock valued at $1,289,000 after buying an additional 8,890 shares during the last quarter. 85.59% of the stock is owned by institutional investors and hedge funds.
Shares of SurModics, Inc. (NASDAQ:SRDX) traded down 1.84% during trading on Friday, hitting $24.00. 39,722 shares of the company traded hands. SurModics, Inc. has a 52-week low of $19.86 and a 52-week high of $30.75. The company has a 50-day moving average of $23.91 and a 200-day moving average of $25.24. The stock has a market capitalization of $318.38 million, a PE ratio of 32.88 and a beta of 1.03.
SurModics (NASDAQ:SRDX) last released its quarterly earnings results on Thursday, February 2nd. The company reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.10. SurModics had a return on equity of 13.14% and a net margin of 13.46%. The business earned $17.80 million during the quarter, compared to analysts’ expectations of $15.81 million. During the same quarter in the prior year, the business earned $0.19 earnings per share. The company’s quarterly revenue was up 7.9% compared to the same quarter last year. Equities analysts expect that SurModics, Inc. will post $0.32 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/2486045/surmodics-inc-srdx-position-maintained-by-murphy-pohlad-asset-management-llc.html.
Separately, Zacks Investment Research lowered shares of SurModics from a “hold” rating to a “sell” rating in a research report on Monday, February 6th.
Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.
Want to see what other hedge funds are holding SRDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SurModics, Inc. (NASDAQ:SRDX).
Receive News & Ratings for SurModics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.